Review Papers Claim by Claim

Visual paper analysis: Structural basis for HIV-1 capsid adaption to a deficiency in IP6 packaging

Data plotted above are digitized from the paper's single-cycle infectivity results (group sizes indicated in source figure legend). The key quantitative message: G225R raises KAKA/T8I infectivity from ~2% to ~16% of WT and, in combination with A77V, to ~30% (WT normalized = 100%) Infectivity data (Fig.1i)

The paper reports that WT and KAKA CA require high µM–mM IP6 to assemble into ordered tubes/cones, whereas G225R and KAKA/G225R assemble at far lower IP6 (G225R: ~50 µM; KAKA/G225R: ~5 µM produced visible tubes/cones in negative-stain EM) — plotted here as a schematic shift in IP6 sensitivity based on the authors' assembly and EM counts In vitro assembly data (Fig.3)

Structural & mechanistic synthesis (visual-first)

• High-resolution structure: KAKA/G225R CA hexamer solved by cryoEM at 2.7 Å (PDB 9I8I; EMD-52724). Model reveals ordered density of CA C-terminus extending to inter-hexamer dimer interface (residues ~220–231) absent in previous WT structures CryoEM structure (PDB 9I8I)
• Biophysical mechanism: Rosetta-guided modeling + multiple (7×) 400 ns MD replicates indicate G225R increases C‑tail occupancy at the dimer interface (mean ~20.7% vs. WT ~10.4%), with salt bridges (G225R/R229 ↔ D152, L231 ↔ K199) stabilizing transient tail docking and leading to tighter CTD packing and more compact dimer interfaces — plausible route by which scarce IP6 can still drive mature capsid formation MD simulations & contact analysis
• Functional evidence: (i) Forced-evolution in T-cells selected G225R (and later A77V) that increase mature capsid occurrences and infectivity in KAKA/T8I backgrounds; (ii) IP6-depletion in producer cells confirms mutants remain IP6‑deficient during assembly, so G225R acts during maturation rather than by restoring IP6 packaging Forced-evolution & IP6-depletion experiments

Critical appraisal — strengths, limitations, and blind spots

1. Strengths (high confidence): integrative multimodal evidence (cryoET of immature lattices, high-res cryoEM hexamer, in vitro assembly EM/pelleting, forced evolution, and MD) all point to the same mechanistic model; data and structures are deposited for re-use (EMDB/PDB/Zenodo) enabling reproduction Data deposition statement
2. Limitations / potential biases: (a) in vitro assembly conditions (pH, IP6 concentration, ionic strength) and recombinant CA may not fully recapitulate intracellular maturation; (b) MD occupancy values are sensitive to model setup and restraints (authors restrained helices 1–218); (c) infectivity rescue is partial (max ~30% with A77V), so other factors beyond C-tail stabilization matter; (d) selection in cell lines may yield adaptations specific to those backgrounds and the NL4-3 backbone Limitations disclosed in paper
3. Key blind spots to test next: (i) performance of G225R (and G225S) in primary human cells and across diverse clinical CA backbones; (ii) direct measurement of pentamer incorporation and geometry in G225R capsids (the paper infers pentamer formation/curvature effects but does not directly quantify pentamer:hexamer ratios in native capsids); (iii) kinetic study of maturation PR cleavage timing in G225R vs WT to test whether C-tail ordering perturbs CA‑SP1 processing kinetics.

What would falsify the main interpretation?

Demonstrations that: (A) G225R fails to increase capsid stability or infectivity in primary-cell contexts and clinical CA backgrounds; (B) high-resolution structures of mature capsids from KAKA/T8I/G225R virions show no C‑terminal contacts with dimer interfaces; or (C) alternative second-site mutations (not involving C-terminal interactions) fully restore capsid formation in IP6-deficient contexts would invalidate the specific CA C‑terminal stabilization mechanism proposed here — all experimentally testable.

Practical suggestions to strengthen follow-ups

• Obtain cryoEM/cryoET of native mature cores from KAKA/T8I/G225R virions (not just in vitro CLPs) and quantify pentamer:hexamer distribution and C‑tail density occupancy across particles.
• Measure PR cleavage kinetics and SP1 processing in G225R-containing virions to exclude maturation-timing artifacts.
• Test G225R (and G225S) in primary CD4+ T cells and macrophages and in diverse CA genetic backgrounds to test generality.
• Run site-directed mutagenesis to disrupt modeled salt bridges (e.g., R229A or D152A) to test causality of those interactions for assembly and infectivity rescue.

Conclusions — balanced summary

Zhu et al. (2025) present a convincing, multi-method case that HIV-1 can adapt to IP6-packaging deficiency via a CA C-terminal substitution (G225R) that promotes transient ordering of residues 220–231 at dimer interfaces, lowering the IP6 threshold required for productive mature capsid assembly and partially rescuing infectivity; the work opens new mechanistic questions about CA C‑terminus roles in lattice curvature, pentamer formation and capsid metastability, and provides high-quality structural resources for further testing Overall claim & deposited data